Multiple myeloma is the second most common haematological cancer. Recent innovations have made it possible for relapsed/refractory patients to benefit from the innovative immunotherapy of bispecific antibodies. These antibodies stimulate the immune system to attack tumour cells. The treatment involves an escalating dose of three subcutaneous injections every 2 to 4 days for a total of about 10 days, followed by a weekly treatment phase.
The University Hospital of Toulouse was the first centre in France to offer outpatient dose escalation for this innovative treatment. This form of treatment depends on clinical and logistical feasibility. Where appropriate, patients are treated in a conventional unit. An analysis carried out at Toulouse University Hospital suggests a response to treatment, with no increased risk of complications in the outpatient setting. Patients' quality of life may also be unaffected. In addition, given the increasing demand for care in a context of finite resources, the economic evaluation of healthcare initiatives is becoming essential if we are to maintain a high-quality healthcare system that is accessible to all.
Relapsed and/or refractory multiple myeloma
Treated with teclistamab, elranatamab ou talquetamab
More than 18 years old
Having received the information from the study and not having objected to participate
Illiterate subjects or those with a language barrier
Study proposed during haematology consultation at the IUCT-Oncopole, detailing the care plan.
Cohort
Prospective
Not listed
Efficiency
Cost of the procedure for health system and quality-adjusted life year calculated from the generic EQ-5D-5L questionnaire
Click on the lead sponsor to view all of their trials.
